Preclinical animal study

Administration of nicotinamide mononucleotide suppresses the progression of age-related hearing loss in mice

Kouya Hattori et al. · Hearing Research · 2025

Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic contextResearch area: Auditory aging
DesignPreclinical longitudinal intervention study of age-related hearing loss in mice with auditory and inner-ear molecular analyses
PopulationAging mice
SampleMultiple treated and control mouse cohorts; see publication
InterventionNMN administered during progression of age-related hearing loss
EndpointsAuditory function; Inner-ear NAD+; Age-related hearing-loss progression; Inner-ear gene expression; Metal-ion-binding-related pathways

What the publication reported

This mouse study tested whether NMN altered the progression of age-related hearing loss.

NMN-treated mice showed slower deterioration in auditory measures, increased NAD+ in inner-ear tissues, and changes in gene-expression pathways including metal-ion-binding-related genes.

The findings are preclinical and all authors were affiliated with Meiji Holdings. They do not show that NMN prevents or treats hearing loss in people.

Key findings

  • NMN attenuated progression of age-related hearing loss in the mouse model.
  • Inner-ear NAD+ levels increased with NMN administration.
  • Inner-ear gene-expression patterns changed, including suppression of metal-ion-binding-related genes.
  • The study was conducted entirely in mice.

What it cannot establish

  • Mouse study only.
  • All authors were affiliated with a commercial company.
  • Auditory biology and dosing may not translate directly to humans.
  • No human hearing outcomes were studied.
HealthspanX claim boundary: This study does not establish that NMN prevents, slows or treats age-related hearing loss in humans.

Continue reviewing

Return to the complete evidence library.

Evidence Center Ultra Pure NMN

Source fields verified